The findings provide initial clinical evidence for an approach that could address difficult radiation-treatment problems, although the study was small and did not report a direct comparison with conventional care. The peer-reviewed study, published in the International Journal of Radiation Oncology, Biology, Physics on August 14, 2026, examined superficial skin and soft-tissue malignancies treated with a specialized radiation-delivery system. Researchers treated 36 patients with 46 tumors, of which 40 could be evaluated.

The cancers included advanced skin cancers such as melanoma and squamous cell carcinoma, as well as soft-tissue sarcomas. Ninety percent of patients had received at least two previous cancer therapies, and all tumors were resistant to other treatments. The population was therefore heavily pretreated, while the focus on accessible surface tumors limits the findings to the type of malignancies and clinical setting studied.

Conventional radiotherapy aims to destroy cancer cells while limiting damage to surrounding healthy tissue. That balance is particularly challenging when a tumor requires a high radiation dose but lies close to an organ or structure whose function needs to be preserved. Scott Lester, a radiation oncologist at Mayo Clinic Comprehensive Cancer Center, described tumors requiring high doses that infiltrate sensitive parts of the body as particularly formidable.

To address the delivery problem, Mayo researchers developed a tungsten collimator that divides a conventional radiation beam into beamlets 0.5 millimeters wide, spaced 1 millimeter apart from center to center. The device creates alternating areas of high and low radiation exposure, called peaks and valleys. The intended advantage of this spatial pattern is that healthy tissue in the low-exposure valleys may have more opportunity to repair and regenerate than it would under a more uniform treatment field, while the narrow high-exposure peaks deliver concentrated radiation to the target.

The clinical findings were consistent with that design: patients experienced fewer radiation-related side effects than are typically seen with conventional radiation despite receiving higher doses in the targeted areas. Researchers also observed healing of tissue alongside control of tumors. Treatment could be completed in two or three sessions instead of the 10 to 30 sessions that may be required with conventional radiotherapy, reducing the number of visits for patients participating in this trial.

Among the 46 tumors, 39, or 85%, received minibeam radiotherapy alone. Seven tumors, or 15%, also received planned conventional radiation therapy. At a median follow-up of approximately 15 months, 22.5% of the 40 evaluable tumors had disappeared, 25% had shrunk and 45% remained stable.

The estimated local control rate at 12 months was 89% overall and 92% among tumors receiving minibeam radiotherapy alone. Local control meant that the cancer had not progressed in the treated area. These percentages describe outcomes observed in this trial; the study did not report a direct comparison with a conventional-treatment group.

Changes in tumor size were accompanied by substantial symptom relief. Patients reported benefits that included relief from pain and bleeding and restoration of daily physical functions, with the study team reporting improved symptoms in 86% of participants. “The study suggested a compelling benefit to quality of life for patients, from relief from pain and bleeding to restoring daily physical functions,” said Kimi Chauhan, a resident in radiation oncology at Mayo Clinic and co-first author.

Michael Grams, a radiation oncology medical physicist and the other co-first author, said the encouraging aspect was that patients tolerated the higher radiation doses even though many had cancers that had resisted previous treatments. One of the trial’s more unexpected observations involved cancer responding outside the area that received minibeam radiation. In 11% of patients, cancer outside the treated area responded even though the patients received no other cancer treatment.

This phenomenon is known as an abscopal response, which occurs when radiation delivered to one tumor is associated with a response in cancer elsewhere in the body. Mayo investigators said the observation suggests that minibeam radiotherapy may affect tumor biology and interact with the immune system. The trial did not establish how often the response will occur, how long it will last or whether minibeam treatment is responsible for it, but the finding identifies an effect that the team is now studying.

Robert Mutter, chair of research in Mayo Clinic’s Department of Radiation Oncology, said the results suggest that an ablative dose may not need to cover every part of a tumor in the same way. He said minibeam radiotherapy may expose distinct ways in which tumors die and could potentially be used to stimulate immune activity against cancer. “This represents an important shift in how we think about radiotherapy because our results suggest that you don't necessarily need to treat all of the tumor with an ablative dose,” Mutter said.

Researchers are conducting laboratory studies to understand the mechanisms that trigger the immune response and which patients are most likely to benefit from minibeam radiotherapy. The immediate development program includes an ongoing phase 1 clinical trial testing increasing doses of minibeam radiotherapy. The team is also developing studies of minibeam radiotherapy in early-stage breast cancer in combination with immunotherapy and during surgery for unresectable pancreatic cancer.

These investigations extend the approach beyond the superficial skin and soft-tissue malignancies included in the initial study. The reported outcomes belong to the completed trial in heavily pretreated patients and should not be interpreted as results from those planned studies. Overall, the first clinical evaluation found encouraging tumor control, symptom relief and tolerability with minibeam radiotherapy in patients with superficial malignancies resistant to other treatments.

Its most distinctive features are the submillimeter beamlets, concentrated high-dose regions separated by lower-exposure valleys and a treatment schedule of only two or three sessions. The study also produced an unexpected immune-related observation in 11% of patients, adding a new avenue for investigation.

Subject of Research: Clinical evaluation of minibeam radiotherapy for superficial skin and soft-tissue malignancies

Article Title: Mayo Clinic first to study minibeam radiotherapy in patients with difficult-to-treat cancers

Article References: Mayo Clinic first to study minibeam radiotherapy in patients with difficult-to-treat cancers. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: minibeam radiotherapy, radiation oncology, superficial tumors, treatment-resistant cancer, melanoma, squamous cell carcinoma, soft-tissue sarcoma, tumor control, abscopal response, cancer immunology, Mayo Clinic, Mayo

The research combined a multicenter contouring exercise with a retrospective recurrence-mapping analysis. Ten radiation oncologists from eight centers independently delineated the prostate-bed CTV in one postoperative case. Agreement was summarized using the Dice similarity coefficient, or DSC, and the 95th-percentile Hausdorff distance, or HD95. The mean pairwise DSC was 0.767 ± 0.046, and the mean HD95 was 8.244 ± 2.347 mm. The investigators reported considerable interobserver variation, particularly around the bladder. Because the exercise involved a single postoperative case, the measurements characterize agreement for that case rather than the full anatomical and clinical variation encountered in routine practice.

For the recurrence analysis, the investigators assigned PSMA PET-positive prostate-bed lesions to an exploratory framework containing six anatomical zones. In addition to the bladder-neck and vesicourethral anastomotic regions, the retrovesical area, Zone 5b, contained 17 of 97 events, or 17.5%, and the dorsolateral perivesical region, Zone 5a, contained 12 events, or 12.4%. The cranial seminal-vesicle-bed region, Zone 6, contained seven events, while the ventral perivesical region, Zone 4, contained only two of 97 events, or 2.1%. The observed maximum extents were 1.3 cm for the 12 Zone 5a events and 3.0 cm for the seven Zone 6 events. These figures describe the extent of recurrence observed in this sample; they do not establish universally safe CTV boundaries or predict recurrence patterns in all patients after surgery.

The researchers also assessed whether recurrence centroids were covered by CTV definitions from the ESTRO-ACROP 2023, GFRU 2020, and RTOG 2010 guidelines. At the patient level, all identified recurrence centroids were covered in 54 of 63 patients by ESTRO-ACROP, or 85.7% (95% confidence interval, 75.0%–92.3%). Coverage was 52 of 63 patients, or 82.5% (95% confidence interval, 71.4%–90.0%), for GFRU and 53 of 63 patients, or 84.1% (95% confidence interval, 73.2%–91.1%), for RTOG. These results are centroid-based assessments and therefore do not demonstrate that every portion of every recurrence was contained within the corresponding CTVs.

Overall, the study found that PSMA PET-positive recurrences were unevenly distributed within the prostate bed after radical prostatectomy and that radiation oncologists showed notable variation when contouring postoperative targets. The low event count in the ventral perivesical region provides an imaging-based rationale for further evaluation of CTV boundaries in that area, while the contouring results underscore the variation around the bladder. The findings may help inform future studies of postoperative target-volume refinement, but the authors emphasized that validation in larger multicenter cohorts is required. The study did not test whether changing any guideline boundary would improve clinical outcomes, and the contouring exercise and retrospective recurrence analysis do not establish a causal effect of CTV size on recurrence or treatment success.

Subject of Research: Postoperative prostate-bed recurrence mapping and radiation target-volume delineation

Article Title: PSMA PET recurrence mapping and guideline coverage after radical prostatectomy: implications for postoperative prostate bed CTV delineation

Article References: Qi, X., Zhang, H., Chen, C., Wu, J., Liao, X., Zhang, J., He, L., Lu, N., Shen, Y., Wang, H., Zhong, Q., Li, Y., Zhang, M., Gao, X., & Li, H. (2026). PSMA PET recurrence mapping and guideline coverage after radical prostatectomy: implications for postoperative prostate bed CTV delineation. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02931-x

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02931-x

Keywords: PSMA PET, prostate cancer, radical prostatectomy, prostate bed, recurrence mapping, salvage radiotherapy, clinical target volume, radiation oncology, interobserver variation, guideline coverage, PSMA, recurrence

The technique, known as deep inspiration breath-hold, or DIBH, is not new. When a patient inhales deeply and holds her breath, the lungs expand, the diaphragm drops, and the heart is physically pulled away from the chest wall and out of the path of the radiation beam. The effect is geometric rather than pharmacological: by shifting anatomy, clinicians can spare healthy tissue without weakening the treatment aimed at the breast. What has remained murky is the degree to which individual anatomy determines how much protection each patient actually gains.

In the study, published in Frontiers in Oncology, a team led by Yanli Cui and Shuai Xu enrolled 17 patients with stage I left-sided breast cancer who had undergone breast-conserving surgery between July 2023 and July 2024. Each patient underwent two separate CT simulation scans—one while breathing freely and one while performing DIBH with the help of an Active Breathing Coordinator system, which monitors airflow and locks the airway at a preset inspiratory volume. From each scan, the team generated a full intensity-modulated radiation therapy plan using identical prescription doses and optimization objectives, allowing a direct, within-patient comparison of how the same treatment would deposit dose under the two breathing conditions.

The dosimetric results were consistent and statistically significant across the board. The mean dose to the left lung fell from 12.69 Gy under free breathing to 11.61 Gy with DIBH, while the volumes of lung receiving 20 Gy (V20) and 30 Gy (V30) also dropped significantly. The heart fared even better: mean heart dose declined from 5.83 Gy to 5.02 Gy, and the volumes receiving 20, 30, and 40 Gy were all significantly reduced. The benefits extended to cardiac substructures as well. The mean dose to the left ventricle fell from 7.61 Gy to 6.40 Gy, the right ventricle from 5.53 Gy to 4.58 Gy, and the left anterior descending coronary artery—the vessel most closely associated with radiation-induced cardiac events—from 22.76 Gy to 18.65 Gy.

Those numbers matter because of what earlier epidemiology has established. A landmark 2013 analysis by Sarah Darby and colleagues in the New England Journal of Medicine found that the risk of ischemic heart disease in irradiated breast cancer patients rose roughly 7.4 percent for every additional Gray of mean heart dose. Against that benchmark, a reduction of nearly 0.8 Gy in mean cardiac dose, and more than 4 Gy to the LAD, represents a potentially meaningful decrement in lifetime cardiovascular risk—though the authors of the new study are careful to note that dosimetric gains cannot be directly translated into clinical outcomes without long-term follow-up.

The more novel contribution of the work lies in its attempt to explain the variability. The researchers measured a battery of anatomical parameters on each patient’s scans: the maximum cardiac margin distance (MCMD), a measure of how close the heart comes to the chest wall near the treatment field; the three-dimensional displacement of the heart’s geometric center between the two breathing states; the total volume of cardiac displacement; the heart-to-breast distance; and the change in lung volume induced by deep inspiration. They then correlated these measurements with the dosimetric changes observed between plans.

Several relationships emerged. Under DIBH, the MCMD was positively correlated with mean heart dose, meaning patients whose hearts sat closer to the chest wall received higher doses even with the breath-hold technique. More tellingly, the change in MCMD between free breathing and DIBH was negatively correlated with heart dose parameters—patients whose hearts moved farther from the chest wall during deep inspiration tended to gain more cardiac sparing. The change in MCMD correlated negatively with mean heart dose (r = -0.516), heart V20 (r = -0.538), heart V30 (r = -0.578), heart V40 (r = -0.575), and the mean doses to both the left and right ventricles.

The heart, it turns out, does not simply retreat in one direction. The team found that during DIBH the heart shifted predominantly along the anterior-posterior axis, with displacement ranging from 2.5 to 27.6 millimeters and averaging about 9 millimeters. Displacement along that axis was itself negatively correlated with mean heart dose. The total cardiac displacement volume ranged from about 62 to 191 milliliters, and patients with larger displacement volumes showed greater reductions in mean heart dose (r = 0.689). Meanwhile, the average increase in lung volume between the two breathing states was a substantial 1,314 milliliters, and that expansion correlated with posterior cardiac displacement, with changes in heart-to-breast distance, and—negatively—with the mean dose to the LAD under DIBH.

Taken together, these findings sketch a mechanical picture of why DIBH works and why it works unevenly. Deep inspiration inflates the lungs, and the inflated lungs push the heart backward and downward, away from the tangential radiation beams that treat the breast. Patients whose anatomy permits a larger excursion—more compliant lungs, more mobile hearts, more room in the thorax—reap larger dose reductions. Those whose hearts remain close to the chest wall even at full inspiration gain less. In principle, this suggests that a quick anatomical assessment at simulation could identify which patients stand to benefit most, though the authors explicitly caution that their exploratory correlations, drawn from a small single-center cohort without correction for multiple comparisons, are hypothesis-generating rather than practice-changing.

The study’s limitations are candidly acknowledged. Seventeen patients is a small sample; the analysis was retrospective; no long-term clinical outcomes such as cardiac events or pneumonitis were assessed; and the anatomical parameters have not been validated in an independent cohort. Still, the work adds a useful layer to a growing literature that has moved beyond asking whether DIBH is effective—it clearly is—to asking which patients gain the most and why. If the correlations hold up in larger, multicenter studies, simple geometric measurements taken during routine CT simulation could become a practical tool for personalizing respiratory management in breast radiotherapy, ensuring that the patients who need cardiac protection most are the ones who get it.

Subject of Research: Dosimetric effects of deep inspiration breath-hold in postoperative radiotherapy for left-sided breast cancer

Article Title: Dosimetric benefits of deep inspiration breath-hold in postoperative radiotherapy for left-sided breast cancer after breast-conserving surgery: an anatomical parameter-based analysis

Article References: Cui, Y., Xu, S., Wang, X., Huo, L., Wen, J., Hao, L., Wang, X., Zhang, Q., & Duan, H. (2026). Dosimetric benefits of deep inspiration breath-hold in postoperative radiotherapy for left-sided breast cancer after breast-conserving surgery: an anatomical parameter-based analysis. Frontiers in Oncology, 16, Article 1917416. https://doi.org/10.3389/fonc.2026.1917416

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1917416

Keywords: deep inspiration breath-hold, left-sided breast cancer, radiotherapy, cardiac dose, lung dose, dosimetry, IMRT, breast-conserving surgery, left anterior descending coronary artery, cardiac displacement, organ at risk sparing, radiation oncology

The research, led by Oğuzhan Türksayar of Başakşehir Çam and Sakura City Hospital in Istanbul and colleagues at institutions across Türkiye, focused on 17 brain metastases treated in 12 consecutive patients who received single-session Gamma Knife radiosurgery. Each patient underwent dynamic contrast-enhanced MRI before treatment and again at the four-to-eight-week mark. Rather than simply observing whether lesions shrank, the team used pharmacokinetic modeling to quantify how the blood-brain barrier and tumor vasculature were behaving, extracting parameters that reflect the movement of contrast agent between blood vessels and tumor tissue.

The technical core of the study lies in the Tofts pharmacokinetic model, a mathematical framework that describes how gadolinium-based contrast material leaks from blood plasma into the extravascular extracellular space of tissue. From this model, the researchers derived several quantitative parameters. The volume transfer constant, known as Ktrans, measures how quickly contrast crosses from the vascular compartment into tissue, serving as a proxy for vascular permeability and blood flow. Kep, the rate constant, describes how rapidly contrast returns from tissue back to the plasma, while Ve represents the fraction of tissue volume occupied by the extravascular extracellular space. The team also measured the initial area under the concentration-time curve, or iAUC, a semiquantitative indicator of early contrast enhancement that captures the first blush of agent entering the lesion.

In addition to these model-based parameters, the researchers extracted semiquantitative features directly from the signal-intensity curves generated during the dynamic scan, including the upslope and the initial gradient of enhancement. These metrics do not require pharmacokinetic assumptions, making them quicker to compute, but they are also more sensitive to variations in scanning protocol. By combining both approaches, the study aimed to determine which measurements best captured the biological consequences of radiation in the earliest phase of treatment.

The results showed a consistent pattern. After radiosurgery, Ktrans, Kep, and iAUC all decreased significantly across the treated lesions, and these reductions remained statistically meaningful even after the researchers applied Benjamini-Hochberg false discovery rate correction, a conservative statistical adjustment designed to guard against false positives when many comparisons are made. The initial gradient also decreased in unadjusted analysis, but this finding did not survive correction. In practical terms, the tumors’ permeability-surface characteristics declined measurably within weeks of treatment, suggesting that radiosurgery was already altering the abnormal vasculature that sustains metastatic growth.

Response classification followed the RANO-BM criteria, the standardized framework developed by the Response Assessment in Neuro-Oncology working group for evaluating brain metastases. Of the 17 lesions, six, representing 35.3 percent, were classified as partial response, while eleven, or 64.7 percent, showed stable disease. Notably, no lesion progressed during this early window, and none achieved complete response, which is typical at such an early checkpoint since tumor shrinkage lags behind vascular change.

The most provocative finding emerged when the researchers examined whether the magnitude of imaging change tracked with the degree of response. In unadjusted analyses, the percentage change in Ktrans was associated with concurrent early radiologic response, with a Spearman correlation coefficient of negative 0.553, and the percentage change in upslope showed a similar association with a coefficient of negative 0.503. Lesions classified as partial response also showed a greater absolute reduction in Ktrans than stable-disease lesions before correction for multiple comparisons. However, the authors are careful to note that none of these between-group or correlation findings survived false discovery rate correction, a caveat that colors the entire study’s conclusions.

This statistical honesty is a defining feature of the work. The researchers label their findings as hypothesis-generating and explicitly state that they require validation in larger, adequately powered, and methodologically standardized cohorts before any clinical application. Recognizing that their small sample involved multiple lesions per patient, which can inflate statistical confidence, they performed a sensitivity analysis using only one lesion per patient. The direction of the Ktrans difference remained consistent with the lesion-level analysis, offering some reassurance that the signal, while not statistically robust in a sample of this size, was not an artifact of clustering within individual patients.

The implications, if confirmed, could be substantial. Early identification of nonresponding lesions would allow oncologists to adjust treatment sooner, whether by adding systemic therapy, planning repeat radiosurgery, or intensifying surveillance, rather than waiting months for conventional scans to reveal failure. Dynamic contrast-enhanced MRI is already available on most modern clinical scanners and can be added to routine follow-up protocols, though its pharmacokinetic modeling demands careful attention to acquisition parameters. The prospective design of this study, with baseline and early post-treatment imaging performed under controlled conditions, strengthens its foundation compared with retrospective analyses, and the lesion-level approach provides fine-grained detail about how individual metastases behave rather than averaging across patients.

For now, the study stands as an early but carefully executed proof of concept. Brain metastases affect a large proportion of patients with advanced cancer, and stereotactic radiosurgery is one of the most common treatments delivered to them, making any tool that accelerates response assessment clinically valuable. The Turkish team’s work demonstrates that measurable vascular changes appear within four to eight weeks of Gamma Knife treatment and that Ktrans, the volume transfer constant, was the most consistent parameter associated with early radiologic response in unadjusted analyses. The road from exploratory association to clinical decision-making runs through larger, standardized, multi-center trials, but this study charts a plausible path toward a future in which the effectiveness of radiation against brain tumors can be read not just in their size, but in the chemistry of their blood vessels.

Subject of Research: Early dynamic contrast-enhanced MRI biomarkers of radiologic response after stereotactic radiosurgery for brain metastases

Article Title: Early DCE-MRI changes and concurrent radiologic response after stereotactic radiosurgery for brain metastases: a prospective exploratory study

Article References: Türksayar, O., Öner, A. Y., Cindil, E., Erpolat, P., & Emmez, H. (2026). Early DCE-MRI changes and concurrent radiologic response after stereotactic radiosurgery for brain metastases: a prospective exploratory study. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02756-8

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02756-8

Keywords: DCE-MRI, stereotactic radiosurgery, brain metastases, Ktrans, Tofts pharmacokinetic model, Gamma Knife, RANO-BM criteria, treatment response assessment, blood-brain barrier, MRI biomarkers, false discovery rate, radiation oncology

The study, published in Breast Cancer Research and Treatment, drew on the National Cancer Database, a hospital-based registry that captures roughly seventy percent of newly diagnosed cancers in the United States. Researchers led by Dylan S. Brokaw and Austin D. Williams of Fox Chase Cancer Center identified 316,324 women aged 50 to 69 who were diagnosed between 2012 and 2022 with early-stage, hormone receptor-positive, HER2-negative breast cancer and who underwent breast-conserving surgery as their first treatment. This tumor subtype is among the most favorable in oncology, and it is precisely the population in which both surgical and radiation de-escalation have been validated.

The two de-escalation strategies in question target different parts of the treatment pathway. The first is the omission of sentinel lymph node biopsy, the surgical sampling of the first lymph nodes to which breast cancer typically spreads. Although far less invasive than the full axillary dissections of the past, sentinel node biopsy still carries risks of lymphedema, chronic pain, and restricted shoulder movement. The second strategy is accelerated partial breast irradiation, or APBI, which concentrates radiation on the tumor bed rather than the whole breast, shortening treatment and reducing exposure of healthy tissue. Randomized trials, including the APBI-IMRT-Florence trial and NSABP B-39/RTOG 0413, have shown comparable cancer control to whole breast irradiation in appropriately selected patients.

What the researchers found was a striking asymmetry. Radiation de-escalation has been embraced: APBI use more than doubled over the study period, rising from about eight percent of patients in 2012 to 16.5 percent by 2022, with a particularly sharp jump after the 2016 update of the ASTRO guideline that expanded APBI recommendations beyond clinical trial settings. Surgical de-escalation, by contrast, barely moved. Sentinel node biopsy was omitted in only about two percent of patients overall, peaking at 2.6 percent in 2016 before dipping to 1.4 percent in 2019 and recovering only partially to 1.8 percent by 2022. Meanwhile, complete axillary dissection declined steadily from 16.4 percent to 4.2 percent, reflecting the earlier and more universally accepted transition from full nodal removal to sentinel sampling.

The central finding, however, concerned the combination of the two strategies. Dual de-escalation, defined as omitting sentinel node biopsy while delivering APBI, was performed in fewer than 0.30 percent of eligible patients in every single year of the eleven-year study. After a modest uptick beginning in 2018, the rate plateaued at roughly 0.23 to 0.26 percent. In other words, even among women whose tumors were small, low-grade, and hormone-driven, the overwhelming majority still underwent both node sampling and either whole breast irradiation or no radiation at all, but almost never the paired minimal approach.

The authors argue that this reluctance is not irrational. Omitting sentinel node biopsy eliminates pathological staging of the axilla, information that can influence decisions about systemic therapy. At the same time, replacing whole breast irradiation with APBI reduces the incidental radiation dose that reaches the low axilla, a dose that may otherwise suppress subclinical nodal disease. Combining the two could therefore create a staging and treatment gap: a patient with undetected nodal involvement receives neither the diagnostic procedure nor the comprehensive radiation field that might have addressed it. The degree to which whole breast irradiation actually treats the axilla varies with beam angle, field borders, and technique, but clinicians have historically viewed it as a partial safeguard, and removing that safeguard without knowing nodal status introduces uncertainty about locoregional control.

Importantly, the study period ended in 2022, before the publication of the trials that have since transformed this debate. The SOUND trial, reported in 2023, and the INSEMA trial, reported in 2025, both demonstrated that omitting sentinel node biopsy is non-inferior to performing it in clinically node-negative patients with small tumors and negative preoperative axillary ultrasound. The BOOG 2013-08 trial has added further support. The patterns documented in this analysis therefore represent a pre-trial baseline: a portrait of how cautiously clinicians behaved when extrapolating from older evidence, chiefly the CALGB 9343 trial and the 2016 Choosing Wisely recommendation, both of which applied only to women aged 70 and older.

The multivariable analysis revealed who was most likely to receive de-escalated care, and the patterns were consistent across all three outcomes. Small clinical T1 tumors, ductal rather than lobular histology, low tumor grade, and older age all predicted de-escalation, while larger, higher-grade, lobular tumors predicted adherence to standard treatment. Institutional factors mattered even more. Treatment at an academic or research program was associated with nearly twice the odds of sentinel node biopsy omission and more than twice the odds of dual de-escalation compared with community cancer centers, a difference the authors attribute to multidisciplinary tumor boards, clinical trial participation, and earlier familiarity with emerging data. Higher household income was also associated with combined de-escalation, echoing prior evidence that socioeconomic advantage facilitates access to complex treatment decisions. Notably, Black and Asian patients were significantly less likely than White patients to receive APBI, and uninsured patients were less likely to receive it than those with Medicare or private insurance, highlighting equity concerns in the diffusion of new techniques.

One further distinction emerged from the data: the difference between structured de-escalation and simple omission of therapy. Among patients whose sentinel node biopsy was skipped, thirty percent received no radiation at all, compared with just six percent of those who underwent node sampling. The authors suggest that the same vulnerable patients who benefit most from avoiding additional surgery may also struggle to complete multi-week radiation courses, whether because of patient preference, transportation barriers, or other unmeasured factors. Shortened, targeted regimens like APBI could offer these patients the benefit of adjuvant treatment without forcing an all-or-nothing choice, which makes the rarity of combined de-escalation all the more consequential.

The study has the limitations inherent to registry research: it cannot capture preoperative axillary imaging, adherence to hormone therapy, patient preferences, or the clinical reasoning behind each decision, and oncologic outcomes beyond survival were unavailable. Still, its message is clear. A small vanguard of clinicians, concentrated in academic centers, began pairing surgical and radiation de-escalation years before prospective evidence existed, while the broader oncology community waited. With the SOUND and INSEMA results now in hand, the question is no longer whether sentinel node biopsy can be omitted in selected patients, but whether the two de-escalations can be safely stacked. The authors call for prospective studies to define the safety, optimal patient selection, and quality-of-life outcomes of combined strategies, and their dataset provides the reference point against which any post-trial acceleration can be measured. Until those data arrive, they conclude, careful multidisciplinary evaluation and shared decision-making remain the essential safeguards for women with low-risk disease.

Subject of Research: Practice patterns in combined de-escalation of axillary surgery and adjuvant radiation for early-stage HR-positive/HER2-negative breast cancer

Article Title: National trends in dual de-escalation of axillary surgery and adjuvant radiation in early-stage HR+/HER2- breast cancer

Article References: Brokaw, D. S., Kozian, L., Chang, C., Shulman, R. M., Bleicher, R. J., So, A., Aggon, A. A., & Williams, A. D. (2026). National trends in dual de-escalation of axillary surgery and adjuvant radiation in early-stage HR+/HER2- breast cancer. Breast Cancer Research and Treatment, 220(1), Article 6. https://doi.org/10.1007/s10549-026-08106-0

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08106-0

Keywords: breast cancer, de-escalation, sentinel lymph node biopsy, accelerated partial breast irradiation, axillary surgery, radiation oncology, National Cancer Database, HR-positive HER2-negative, breast-conserving surgery, SOUND trial, INSEMA trial, surgical oncology

The trial, known as NRG-GU003, compared two distinct ways of fractionating radiation after prostatectomy. The conventional approach, abbreviated COPORT, delivered a total dose of 66.6 Gy to the prostate bed in 37 fractions of 1.8 Gy each. The hypofractionated approach, abbreviated HYPORT, delivered a slightly lower total dose of 62.5 Gy in just 25 fractions of 2.5 Gy each, compressing the entire course into approximately five weeks. Fractionation is a central concept in radiation oncology: because normal tissues repair sublethal DNA damage between treatments, splitting a dose into many small fractions spares healthy structures such as the bladder and rectum. Hypofractionation deliberately uses larger daily doses over fewer visits, exploiting improvements in treatment precision while betting that the tumor responds more strongly to bigger per-fraction doses than surrounding organs do. The trade-off is that each fraction tests the tolerance of nearby healthy tissue more aggressively.

The study enrolled 296 eligible patients, a sample size that gives the comparison meaningful statistical weight. Before randomization, investigators stratified participants by their baseline scores on the Expanded Prostate Cancer Index Composite, a validated questionnaire that captures urinary and bowel function, and by whether they had previously received androgen deprivation therapy, the hormonal treatment often paired with radiation in high-risk disease. Patients were then randomly assigned to one of the two radiation schedules. The primary objective was to determine whether HYPORT was noninferior to COPORT with respect to patient-reported urinary and bowel symptoms at two years, a design that asks not whether the shorter schedule is better, but whether it is acceptably close to the standard.

By that primary yardstick, the shorter schedule held up. The mean changes in patient-reported outcomes from baseline to five years were similar between the two arms for bowel symptoms, urinary symptoms, and overall quality of life as measured by the EQ-5D instrument. Bowel symptom scores shifted by 0.6 points in the conventional arm versus minus 2.0 points in the hypofractionated arm, a difference that was not statistically significant. Urinary symptom scores moved by minus 5.7 versus minus 8.0 points, and EQ-5D scores by minus 0.01 versus 0.0, again without significant differences. In practical terms, patients treated in five weeks reported essentially the same subjective experience over five years as those treated across seven.

Cancer control outcomes also favored equivalence. With a median follow-up of seven years, biochemical failure at five years occurred in 18 percent of men treated conventionally versus 21 percent of men treated with the shorter schedule, a difference that did not reach statistical significance. Biochemical failure, detected through rising PSA levels, is the earliest and most closely watched signal of returning disease after surgery. Across both arms, 31 deaths were reported in total, including four from prostate cancer, underscoring that neither schedule produced an excess of fatal events. For a disease in which postoperative radiation is delivered specifically to preserve the chance of cure, the demonstration that the compressed course did not compromise long-term control is the trial’s most consequential finding.

The picture grows more nuanced, however, when toxicity is examined through the physician’s eyes rather than the patient’s. At five years, grade 3 adverse events of any kind were more common in the hypofractionated arm, occurring in 16 percent of patients compared with 7 percent in the conventional arm, a statistically significant difference. The excess was concentrated in renal and urinary disorders, which affected 13 percent of hypofractionated patients versus 3 percent of conventional patients. Within that category, noninfective cystitis, inflammation of the bladder, occurred in 7 percent of the shorter-schedule patients and none of the conventional patients, while hematuria, blood in the urine, occurred in 6 percent versus 0.7 percent. Importantly, no grade 4 or grade 5 radiation-related adverse events were recorded in either arm, and the time to onset of grade 3 events did not differ between groups.

Mark Buyyounouski, MD, MS, FASTRO, of Stanford University and lead author of the NRG-GU003 manuscript, framed the results around the practical realities of treatment access. Postoperative radiation, he noted, is an important part of preserving the opportunity for cure in patients with PSA recurrence after prostatectomy, yet the traditional 37 sessions over approximately seven weeks can make treatment difficult for some patients to receive and burdensome for those who do. The findings, he said, show that postoperative radiation can be delivered in a shorter five-week course of 25 treatments without compromising long-term cancer control or patient-reported quality of life. For radiation oncology departments, a 12-fraction reduction per patient translates into meaningful gains in chair time, machine capacity, and patient convenience.

The divergence between what patients report and what physicians record is a recurring theme in modern oncology trials, and Buyyounouski addressed it directly. While long-term patient-reported urinary outcomes were similar, physician-reported grade 3 urologic toxicity was increased with hypofractionation, and the reason for that difference is unknown, he observed. Physician-reported toxicity primarily captures clinical events and the interventions they require, while patient-reported outcomes capture symptoms, function, and how treatment affects daily life. These measures provide different, complementary perspectives on treatment effects. A patient may experience bladder irritation that resolves without dramatic intervention, while a physician may document a clinically significant event requiring medication or procedural management, and the two lenses need not align.

The results were presented during the Clinical Trials Session of the 2026 American Society for Radiation Oncology Annual Meeting in Boston, Massachusetts, placing them before the community of specialists who set fractionation standards worldwide. The trial’s support came from the National Cancer Institute, part of the National Institutes of Health, through grants funding the NCORP research base, the NRG Oncology statistical and data management center, NRG Oncology operations, and imaging and radiation quality assurance. NRG Oncology itself, founded in 2012 as a Pennsylvania-based nonprofit, integrates the legacy research programs of the National Surgical Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group, and operates through more than 1,300 research sites worldwide.

For clinicians weighing the findings in the clinic, the decision will hinge on how much weight to give the toxicity signal against the benefits of a shorter course. Buyyounouski concluded that physicians will need to decide how much weight to give the toxicity findings when choosing a fractionation schedule, particularly when a shorter course could improve access to care, reduce treatment burden, or even make postoperative radiation possible for patients who would otherwise forgo it. A five-week schedule that preserves biochemical control and patient-reported quality of life may extend curative-intent treatment to men for whom seven weeks of daily visits was never realistic, while the modest but real increase in grade 3 cystitis and hematuria gives treating physicians a concrete, quantifiable trade-off to discuss with each patient before the first fraction is delivered.

Subject of Research: Hypofractionated versus conventional postprostatectomy radiotherapy for high-risk prostate cancer

Article Title: Shortened radiation schedule provides similar cancer control and patient-reported outcomes to standard radiation following surgery for high-risk prostate cancer in NRG Oncology trial

Article References: Shortened radiation schedule provides similar cancer control and patient-reported outcomes to standard radiation following surgery for high-risk prostate cancer in NRG Oncology trial. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: prostate cancer, radiation therapy, hypofractionation, postprostatectomy radiotherapy, NRG Oncology, NRG-GU003, clinical trial, biochemical failure, patient-reported outcomes, urinary toxicity, ASTRO, radiation oncology

The patients were not an easy crowd. All had presented with high-risk features at initial diagnosis: the median biopsy Gleason score clustered at 8, more than 42 percent had extraprostatic extension (pT3b), 20 percent already harbored positive lymph nodes at surgery, and over a third had incomplete resections. Yet when their prostate-specific antigen (PSA) began climbing after first-line therapy, modern gallium-68 or fluorine-18 PSMA-PET/CT scans pinpointed the culprits — 172 metastases in total, roughly 80 percent nodal and 20 percent bone — while disease burden remained low, with a median pre-SBRT PSA of just 1.66 ng/mL.

The treatment itself was strikingly uniform. Each PSMA-avid lesion defined the gross target volume, wrapped in a 1-to-5-millimeter planning margin depending on location, and received an ablative dose to the surrounding 70 percent isodose line of either a single 18-to-21-Gy fraction or three 8-Gy fractions. The CyberKnife robotic platform tracked lesions stereoscopically — bone tracking in 92.4 percent of cases, fiducial markers in the rest — allowing sub-millimeter accuracy that spared surrounding bowel, bladder, and spinal cord. Most series treated one or two metastases; the median planning target volume was a mere 3.31 cubic centimeters.

Toxicity data read like a wish list. Across 95 treatment series, 93.5 percent of patients experienced no acute or late adverse events at all. The six acute grade 1 events comprised temporary fatigue, diarrhea, nausea, and single cases of pain, proctitis, and polyuria; only one patient developed a late symptom, a persistently painful bone metastasis. No event exceeded grade 1. That stands in sharp contrast to trials combining SBRT with elective nodal radiation or hormone therapy, where grade 2 and 3 genitourinary and gastrointestinal toxicity rates have reached double digits, and to systemic therapy arms in the STAMPEDE and LATITUDE trials, where 47 to 63 percent of patients suffered grade 3 or worse adverse events.

Local control was equally impressive. Among 117 metastases re-assessed by repeat PET/CT, 89.7 percent remained locally controlled — 93.5 percent for lymph nodes but only 76 percent for bone lesions. The authors attribute the nodal-bone gap to the protective microenvironment of the bone marrow, which shelters cancer cells, and possibly to hypoxia within bone lesions, which blunts radiation efficacy. PSA response after SBRT was seen in 70.5 percent of series, with the median post-treatment nadir falling to 0.58 ng/mL roughly four months after treatment.

The headline endpoints tell the story of a bridge. Median biochemical progression-free survival was 6 months — short by conventional standards, but the strict definition used (a PSA rise of more than 0.2 ng/mL from nadir) and the aggressive histology of the cohort (63 percent with Gleason 8 or higher) make direct comparisons tricky. Median SBRT-free survival, meaning the time before a second course became necessary, was 23 months, and 43 of the 60 patients actually received repeat SBRT courses with no predefined upper limit. Median ADT-free survival reached 32 months, with 85.9 percent of patients still hormone-free at one year and 68.4 percent at two years. A third of the cohort finished follow-up without any treatment escalation whatsoever.

Prognostic modeling identified who fared worst. A high PSA nadir after SBRT, an initial pN1 nodal status at surgery, and a longer time to reach the PSA nadir all predicted shorter biochemical progression-free and SBRT-free survival on multivariable Cox regression. The authors suggest these patients could be steered earlier toward combination approaches — either standard ADT or androgen receptor pathway inhibitors such as abiraterone, enzalutamide, apalutamide, or darolutamide — rather than cycling through repeated focal treatments that may ultimately prove futile.

The rationale for attacking metastases this early rests on evolutionary biology. Genetic analyses of lethal metastatic prostate cancer have shown that the tumor clones responsible for fatal dissemination do not necessarily reside in the primary tumor but can emerge from any single metastasis. Meanwhile, early metastases detected by molecular imaging carry fewer high-risk DNA features and a better survival prognosis than those found later. The logic, then, is to intervene while the disease is still genetically tame — and to save the effective but toxic and finite systemic arsenal for when it is truly needed.

The Charité results compare favorably with prior prospective trials. The STOMP trial reported a median ADT-free survival of 21 months; Siva and colleagues described only a 48 percent two-year ADT-free rate; Mazzola’s bone-only cohort managed 13.5 months. The Berlin cohort’s 32-month median, achieved without ADT contamination and with a uniform ablative dose concept, is among the best reported. The second-largest number of metastases treated in any single analysis also strengthens the dataset, though the authors acknowledge the retrospective design, the absence of a control arm, and the lack of a predefined PSA cutoff triggering re-imaging or re-treatment as critical limitations.

Whether early oligo-recurrences inevitably progress into life-threatening disease remains an open question, and the authors concede that for some patients with gradual progression, observation might have sufficed. Still, they argue that establishing molecular imaging plus focal SBRT as a first go-to option in oligo-recurrent prostate cancer is worthwhile: the procedure is swift, outpatient-based, locally ablative, essentially toxicity-free, and repeatable on demand. For patients anxious about the quality-of-life toll of permanent hormone therapy, the approach offers something rare in oncology — a way to buy nearly three years of normal testosterone levels while the clock on systemic therapy is deliberately held back.

Subject of Research: Health

Article Title: Bridging to systemic therapy: PSMA-PET-based early and repetitive stereotactic body radiotherapy for nodal and bone oligo-recurrent prostate cancer

Article References: Grün, A., Partyka, A., Galler, M., Schlomm, T., Böhmer, D., Miller, K., Zips, D., & Kalinauskaite, G. (2026). Bridging to systemic therapy: PSMA-PET-based early and repetitive stereotactic body radiotherapy for nodal and bone oligo-recurrent prostate cancer. Frontiers in Urology, 6, Article 1738508. https://doi.org/10.3389/fruro.2026.1738508

Image Credits: AI Generated

DOI: 10.3389/fruro.2026.1738508

Keywords: prostate cancer, PSMA-PET, SBRT, oligometastatic, radiation oncology, androgen deprivation therapy, metastasis-directed therapy, Charité Berlin, Bridging, systemic, therapy, PSMA-PET-based

The study, led by Brock J. Gjesdal, Samuel Adida, and Suchet Taori under the senior authorship of neurosurgeon Peter C. Gerszten, drew from a prospectively maintained database of consecutive patients treated between 2002 and 2024. From 600 patients with 936 spinal metastases in the database, the team identified 182 patients aged 70 or older; after excluding those without baseline imaging, 161 patients with 208 metastases formed the final cohort. The median age was 75 years, with 30 patients over 80 and six over 85. Seventy-two percent of the metastases had already been irradiated with conventional external beam radiotherapy, making this predominantly a reirradiation population, and 76 percent received their entire SBRT dose in a single fraction.

The technical sophistication of SBRT is what sets it apart from conventional palliative radiotherapy. While conventional external beam radiotherapy delivers relatively uniform doses across a broad field, SBRT exploits steep dose gradients to concentrate ablative radiation doses within the tumor while respecting the tolerance of the spinal cord. In this cohort, the median single-fraction margin dose was 16 Gy, with a range of 12 to 18 Gy, and multi-fraction regimens delivered a median total margin dose of 24 Gy in two to five fractions. Dose was most commonly prescribed to the 80 percent isodose line, and a planning target volume margin of zero to two millimeters was applied while excluding the spinal cord or cauda equina, which were contoured as the spinal canal or thecal sac plus one millimeter. Treatment was delivered using CyberKnife, Elekta Synergy, and Varian TrueBeam platforms, with image guidance achieved through six-dimensional tracking, daily cone-beam computed tomography, or ExacTrac. Magnetic resonance imaging was registered to the simulation CT for target delineation, and CT myelography was used when metal artifact limited visualization of the neural elements.

The outcomes challenge the assumption that elderly patients are poor candidates for aggressive local therapy. After a median follow-up of nine months, the cumulative incidence rates of local failure were 6 percent at six months, 9 percent at twelve months, 9 percent at twenty-four months, and 10 percent at thirty-six months, with death treated as a competing risk. Vertebral compression fracture rates were similarly low: 4 percent at six months, 7 percent at twelve months, 8 percent at twenty-four months, and 9 percent at thirty-six months. Complete or partial pain response followed 61 of 148 evaluable treatments, representing 41 percent of evaluable cases among 186 symptomatic metastases. Grade one or two radiation toxicity occurred in 18 percent of patients, most commonly pain flare, which was managed with corticosteroids in most cases. Critically, no radiation myelopathy or radiculopathy occurred, and apart from vertebral compression fracture, no grade three or higher toxicity was observed.

But the most scientifically compelling finding is what the researchers did not find. Using Fine-Gray competing-risk models with cluster-robust variance to account for multiple lesions per patient, the team analyzed age as a continuous variable, at clinically relevant thresholds of 75 and 80 years, and with exploratory maximally selected rank statistics that searched for the age cutoff most strongly associated with each outcome. No statistically significant association between age and local failure or vertebral compression fracture was detected under any parameterization. Restricted cubic spline analysis with knots at the fifth, thirty-fifth, sixty-fifth, and ninety-fifth age percentiles confirmed the absence of any overall association or nonlinearity, with confidence intervals obtained from 300 bootstrap replicates resampling patients.

What did predict failure? Tumor biology and spinal mechanics, not the patient’s birth year. On multivariable analysis, gross tumor volume greater than 37 cubic centimeters was independently associated with local failure, with a subdistribution hazard ratio of 6.27, and the Spinal Instability Neoplastic Score, analyzed per point, carried a subdistribution hazard ratio of 1.23. For vertebral compression fracture, only SINS remained independently associated, with a per-point subdistribution hazard ratio of 1.19. These findings suggest that the size of the tumor and the mechanical integrity of the spine, rather than the age of the patient, are the true determinants of treatment success and fracture risk.

Age did matter for one outcome: overall survival. Each additional year of age carried a hazard ratio of 1.05 for death, and Karnofsky Performance Status greater than 70 was independently associated with superior survival, with a hazard ratio of 0.56. Prior conventional radiotherapy was associated with shorter survival, likely reflecting a longer and more advanced disease course rather than harm from reirradiation. Interestingly, the effect of age was not proportional over time: age was not significantly associated with survival during the first twelve months after SBRT but became strongly associated thereafter, with a hazard ratio of 1.14 per year beyond the first year.

The study also revealed a temporal trend in fracture risk that raises important questions about treatment evolution. Vertebral compression fracture risk increased with later treatment year, with a subdistribution hazard ratio of 1.56 per five years, and was higher after linear accelerator treatment compared with robotic CyberKnife delivery. All treatments after 2016 were delivered with gantry-based linear accelerators, and most were multi-fraction, making it impossible to reliably separate the effects of treatment year, platform, and fractionation. Prior or adjuvant immunotherapy also became more common over time, from 7 of 133 treatments in the early period to 16 of 46 in the recent era, potentially reflecting changing patient selection as systemic therapies improved.

Eleven of the 17 vertebral compression fractures required intervention, either percutaneous cement augmentation or open surgical decompression with or without instrumented fusion. This is not a trivial complication, and the researchers acknowledge that most fractures were clinically significant. However, they also note that because vertebral body collapse contributes to the SINS classification and progression of a baseline fracture was counted as a fracture event, the association between spinal instability and fracture may partly reflect pre-existing structural compromise rather than pure treatment effect. The researchers suggest that antiresorptive therapy with bisphosphonates or denosumab prior to SBRT may represent an additional strategy for mitigating fracture risk, and prophylactic cement augmentation with kyphoplasty prior to SBRT has been shown to be safe without compromising treatment planning or delivery.

The findings arrive at a pivotal moment. The incidence of spinal metastases is increasing, particularly among the elderly, and advances in targeted and immunotherapies are prolonging survival, making durable local control increasingly important for maintaining quality of life and functional independence. Yet elderly patients remain underrepresented in randomized controlled trials of spine radiation therapy and may be preferentially treated with conventional radiotherapy based on concerns about bone quality and fracture risk. This study, one of the largest to specifically characterize outcomes in patients aged 70 and older, suggests those concerns may be overstated for appropriately selected patients. The researchers caution that their single-institution retrospective design is subject to selection bias, that the median follow-up of nine months reflects the limited survival of this population, and that no comorbidity index, frailty measure, or geriatric assessment was available. Nevertheless, the consistency of the multivariable associations across all sensitivity analyses, including cause-specific Cox models, Firth-penalized models, and multiple imputation of missing performance status, strengthens the central conclusion: treatment selection for spinal metastases should be guided by tumor characteristics, spinal stability, and overall prognosis rather than chronological age alone.

Subject of Research: Stereotactic body radiation therapy in elderly patients with spinal metastases

Article Title: Stereotactic body radiation therapy in elderly patients with spinal metastases

Article References: Gjesdal, B. J., Adida, S., Taori, S., Zureick, A. H., Choi, S., Flickinger, J. C., Zinn, P. O., Bayley, J. C., Gerszten, P. C., & Sefcik, R. K. (2026). Stereotactic body radiation therapy in elderly patients with spinal metastases. Journal of Neuro-Oncology, 180(2), Article 22. https://doi.org/10.1007/s11060-026-05838-3

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05838-3

Keywords: SBRT, spinal metastases, elderly patients, radiation oncology, vertebral compression fracture, spine oncology, Stereotactic, body, radiation, therapy, elderly, patients

The research, conducted in collaboration with the Society of Chairs of Academic Radiology Departments and the Society of Chairs of Academic Radiation Oncology Programs, took the form of an anonymous survey distributed to department chairs at academic radiology and radiation oncology programs across the United States between June and July 2025. By targeting the leaders who administer and interpret leave policies, the investigators aimed to capture a department-level picture of how paid family and medical leave, commonly abbreviated as PFML, is structured in the academic settings where radiologists and radiation oncologists are trained and employed.

The headline finding is one of broad availability but uneven execution. PFML policies were reported to exist in academic radiology and radiation oncology departments of every specialty, geographic region and department size, suggesting that the era in which physician parents or caregivers had no formal paid leave option at all has largely receded. Yet availability is only the first step. According to the study authors, a significant number of programs surveyed require faculty members to draw down vacation or sick time as part of their leave, a design choice that effectively reduces the total time off a physician can accumulate. The survey also documented wide variability in two structural features that can determine whether leave is genuinely usable: whether leave can be taken in noncontiguous blocks rather than one continuous stretch, and whether the promotion clock can be extended to compensate for time away.

These details matter because the structure of a leave policy shapes how it functions in practice. Requiring physicians to exhaust vacation and sick banks before accessing paid family leave can leave them with little discretionary time off in the years that follow a birth, adoption or serious illness. Restrictions on noncontiguous leave can force a recovering parent or a physician managing a chronic condition to take all protected time in a single block, even when a phased return or intermittent schedule would better serve their health and their family. And when promotion clock extension is inconsistent or unclear, faculty may face a hidden career penalty for taking leave that is nominally available to them, a concern that weighs heavily in specialties where the pathway to tenure and academic advancement is tightly calibrated to years of service.

Kirti Magudia, MD, PhD, assistant professor of radiology at Duke University and an author of the study, framed the results as evidence of a persistent gap between what policies promise and what physicians experience. Paid family and medical leave, she noted, is an important workplace benefit that all radiologists and radiation oncologists can be expected to use at some point during their careers. While the survey results are promising in showing how widespread formal policies have become, she expressed the hope that these policies will continue to improve to support the wellness of the workforce. That framing captures the study’s central tension: the infrastructure for leave exists almost everywhere, but its design and delivery have not converged on a standard that physicians can rely on as they move between institutions.

Perhaps the most striking utilization finding is that most survey respondents reported that fewer than 10 percent of faculty in their departments used leave during the previous year. On its face, such a low figure seems at odds with the demographic realities of a workforce that includes physicians in their childbearing and child-rearing years, as well as clinicians who inevitably face medical events and family caregiving responsibilities. The authors interpret this as another signal of the gap between policy and implementation. Low reported utilization may reflect genuine underuse, whether because physicians hesitate to take leave, because coverage constraints make it impractical, or because the administrative pathway is burdensome. It may also reflect how utilization is counted at the departmental level. Either way, a benefit that fewer than one in ten faculty members access in a given year is not functioning as the routine, expected support that its advocates envision.

Underlying much of the survey’s findings is the problem of clinical coverage. Substantial concerns about who will read the studies, deliver the treatments and staff the services when a physician steps away emerged as a recurring theme among respondents. In radiology, where coverage models are built around continuous interpretation of imaging studies, and in radiation oncology, where treatment courses cannot be paused without clinical consequences, the absence of a single faculty member creates a tangible workload that must be absorbed by colleagues or covered through temporary hiring. The survey suggests that in many departments, no robust system exists for absorbing this workload, which means the practical feasibility of leave often depends on informal goodwill rather than institutional design. That reliance on informal coverage is precisely the kind of structural weakness that makes leave policies feel precarious to the physicians considering them.

The study’s methodology, a chair-level survey rather than a review of written policies or an analysis of personnel records, carries both strengths and limitations worth noting. Chairs are uniquely positioned to describe how leave is administered in their departments, including the informal norms that never appear in an employee handbook. At the same time, self-reported perceptions of policy clarity and utilization may diverge from what faculty themselves experience, and the anonymous design, while encouraging candor, prevents follow-up with individual respondents. The survey period of June to July 2025 also captures a snapshot of a landscape that continues to evolve, as states expand their own paid family and medical leave programs and institutions adjust to a patchwork of federal, state and local requirements.

That patchwork is an important part of the context. In the United States, there is no comprehensive federal mandate for paid family leave, so the benefits available to a physician depend on a combination of institutional policy, state programs where they exist, and the federal Family and Medical Leave Act, which provides unpaid job-protected leave for eligible employees. Academic medical centers therefore occupy a policy space where generous departmental practices can coexist with minimal legal floors, and where a physician relocating from one state or one institution to another may encounter dramatically different entitlements. The variability documented in this survey is a window into that fragmented system, seen from the vantage point of the department leaders who must translate institutional rules into workable schedules.

The implications extend beyond radiology and radiation oncology. Academic medicine has often served as a bellwether for physician workplace policy, and the patterns identified here, including mandatory depletion of vacation banks, unclear promotion protections, coverage anxieties and low utilization, are likely to resonate in other specialties grappling with the same structural questions. For a profession facing well-documented pressures on wellness, burnout and retention, the design of leave policy is not a peripheral administrative detail but a core element of workforce sustainability. The study’s authors, by documenting the extent of inconsistency with survey data rather than anecdote, have given departments and professional societies a concrete baseline against which future reform can be measured. Whether the next survey of academic chairs reports convergence on clear, usable, genuinely supportive leave policies will be one measure of how seriously academic medicine takes the wellness of the physicians it trains and employs.

Subject of Research: Paid family and medical leave policies in U.S. academic radiology and radiation oncology departments

Article Title: JACR study explores discrepancies among paid family and medical leave policies across U.S. academic and radiation oncology departments

Article References: JACR study explores discrepancies among paid family and medical leave policies across U.S. academic and radiation oncology departments. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: paid family leave, medical leave, radiology, radiation oncology, academic medicine, department chairs, survey research, physician wellness, workforce policy, Journal of the American College of Radiology, Duke University, clinical coverage

The most pharmacologically ambitious of the five studies concerns VVD-133214, formerly known as RO7589831, the first clinical-stage covalent inhibitor of Werner helicase ever tested in humans. Werner helicase is a DNA repair enzyme that many tumors become dangerously dependent upon, particularly cancers carrying certain genetic defects that leave them with few redundant ways to fix breaks in their DNA. By covalently locking onto the helicase, the drug disables a molecular lifeline that normal cells can afford to lose but cancer cells cannot. In a Phase 1 trial led by Timothy Yap, professor of Investigational Cancer Therapeutics and vice president and head of clinical development in the Therapeutics Discovery division, the compound demonstrated promising durable antitumor activity while remaining generally well tolerated. The results were first presented in a clinical trials plenary session at the American Association for Cancer Research Annual Meeting 2025 and published in Nature Medicine.

Yap emphasized both the safety signal and the scarcity of alternatives for the patients involved. “VVD-133214 appears generally safe and shows promising antitumor efficacy,” he said. “These are encouraging clinical data, especially because this is a patient population that currently has very limited treatment options. This also further validates Werner helicase as an actionable target, which is exciting because many cancers are highly dependent on it for survival.” The concept of synthetic lethality, in which a drug targets a vulnerability created by a pre-existing tumor defect rather than the defect itself, has already produced clinical successes with PARP inhibitors, and the Werner helicase program suggests the same logic can be extended to a fresh class of DNA repair dependencies. Larger trials will determine whether the durable responses seen at this early stage translate into regulatory progress.

Where the helicase inhibitor is a systemic therapy, the second study is strikingly physical. In the randomized Phase 3 ROADS trial, co-led by Jeffrey Weinberg, professor of Neurosurgery, and Thomas Beckham, assistant professor of CNS Radiation Oncology, surgeons implanted collagen tiles embedded with radioactive cesium-131 directly into the surgical cavity immediately after resecting newly diagnosed brain metastases. This tile-based radiation therapy, known as TBRT and marketed as GammaTile, was compared against the current standard of postoperative stereotactic radiation therapy. It was the first randomized controlled Phase 3 trial to make that comparison, and the results, presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in the Journal of Clinical Oncology, were stark.

After one year, only 1.3 percent of patients who received the implanted tiles experienced recurrence at the surgical site, compared with 15.4 percent of those given standard stereotactic radiation, a roughly twelvefold reduction in local failure. Median overall survival, a key secondary endpoint, reached 42.5 months with tile-based therapy against 17.6 months with standard care. Fewer recurrences also meant fewer salvage procedures, sparing patients repeat surgery or additional radiation courses. “Implanting the radioactive tiles at the time of surgery guarantees that patients receive their treatment immediately, along with focal dose escalation, thereby having meaningful impact on local tumor control,” Weinberg said. “From a patient standpoint, we’re showing that there’s almost four times the length of local control and an increase in overall survival. It’s not just a little difference. It’s a massive difference.” The researchers argue the approach should be considered a standard of care for patients whose brain metastases require surgical resection.

Not every aggressive intervention survived scrutiny. The NRG-BR002 trial, led by Steven Chmura, chair of Breast Radiation Oncology, tested a hypothesis that has generated enormous enthusiasm in recent years: for patients with oligometastatic breast cancer, meaning disease spread beyond the original tumor but confined to only a small number of sites, would eradicating each visible metastasis with stereotactic body radiation therapy or surgery improve outcomes? Advances in these highly focused local treatments have made such metastasis-directed therapy technically straightforward, and many oncologists hoped that removing every detectable lesion might delay progression or even extend life when combined with modern systemic drugs. The randomized trial delivered a clear negative result in patients receiving first-line systemic therapy: targeting individual metastases did not improve either progression-free or overall survival.

“There has been tremendous interest in whether aggressively treating every visible metastatic site could change the natural history of breast cancer for patients with only a few metastases,” Chmura said. “This randomized trial gives us important evidence that, for most patients in this setting, adding local treatment to effective systemic therapy does not improve progression-free or overall survival.” The finding provides important evidence against routinely adding metastasis-directed procedures when effective drug therapy is already controlling the disease, potentially sparing hundreds of thousands of patients each year the burdens of unnecessary radiation and surgery. In oncology, well-designed negative trials are often as transformative as positive ones, and this one may redraw treatment algorithms for limited metastatic breast cancer.

A fourth study addressed prevention rather than treatment, focusing on cascade genetic testing. When a patient is found to carry an inherited cancer-related mutation, such as a pathogenic BRCA1 or BRCA2 variant, their first-degree relatives are offered testing to determine whether they inherited the same risk. In practice, uptake has been inconsistent, often because families receive little more than a letter or a phone call. In the new trial, led by Roni Wilke, assistant professor of Gynecologic Oncology and Reproductive Medicine, cancer patients received personalized support and navigation services from experts throughout the genetic testing process, and their relatives were subsequently significantly more likely to get tested themselves. Notably, nearly half of those relatives carried a BRCA1 or BRCA2 mutation, underscoring how much hereditary risk goes undetected without proactive outreach.

The numbers showed a clear effect of the navigation model: genetic testing uptake for BRCA among at-risk family members rose from 51 percent to 73 percent within six months. “This study demonstrates that simply informing relatives of their inherited cancer risk is not enough,” Wilke said. “When we provided navigation to help people through the testing process, we noticed a meaningful difference in utilization and how soon people completed their testing. This creates new opportunities to enhance screening, prevention and early intervention for several hereditary cancers.” Because carriers of BRCA mutations can benefit from enhanced screening, risk-reducing surgery and preventive strategies, closing this testing gap translates directly into cancers caught earlier or prevented altogether.

The fifth study is computational rather than clinical, and it aims at one of immunology’s deepest puzzles: how do immune cells navigate to precise locations in the body, and why do some tumors attract them while others keep them out? A team co-led by Tao Wang, associate professor of Bioinformatics and Computational Biology, and Linghua Wang, professor of Genomic Medicine and executive director and head of the Center for Cellular Language Intelligence, built an artificial intelligence model that infers the local signaling cues drawing immune cells toward or away from specific tissue neighborhoods. Published in Nature Biomedical Engineering, the tool goes beyond existing spatial technologies that merely map where immune cells sit. It seeks to explain the chemotactic logic behind their positions, identifying attractant signals as well as barriers such as immune-excluding stromal patterns that block infiltration.

“While spatial technologies can show where immune cells are located, this new tool helps us investigate why they gather in certain areas and how they reach and recognize tumor cells,” Wang said. “By identifying local signals that attract immune cells as well as potential barriers that may keep them out, we may be able to identify biomarkers and therapeutic targets that could be used to improve patient outcomes.” Because immune infiltration predicts response to checkpoint inhibitors across many tumor types, a model that reveals why T cells fail to enter a tumor could point the way to rational combinations that dismantle those barriers. The same framework applies to autoimmune disease, where misdirected immune trafficking drives tissue damage.

Viewed together, the five studies sketch a coherent portrait of where cancer medicine is heading: drugs designed around tumor-specific dependencies in DNA repair, delivery devices that fuse surgery and radiotherapy into a single intervention, trials that define when less is more, navigation systems that extend precision medicine to whole families, and computational engines that translate the spatial dialects of the tumor microenvironment. Each result arrived through the kind of multidisciplinary collaboration the institution has built its reputation upon, and each, in its own register, recalibrates the standard of care, whether by raising it with radioactive tiles, lowering it with a negative trial, or reframing it entirely with artificial intelligence.

Subject of Research: Cancer treatment, prevention, and immunology research advances at MD Anderson

Article Title: UT MD Anderson shares latest research breakthroughs

Article References: UT MD Anderson shares latest research breakthroughs. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: MD Anderson, Werner helicase inhibitor, brain metastases, tile-based radiation therapy, oligometastatic breast cancer, cascade genetic testing, BRCA, artificial intelligence, tumor immunology, clinical trials, radiation oncology, precision oncology